Document Detail

Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly.
MedLine Citation:
PMID:  10822319     Owner:  NLM     Status:  MEDLINE    
To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly, patients >65 years of age with supine diastolic blood pressure (BP) > or =90 and < or =110 mm Hg at the end of a 4-week placebo washout period were treated with perindopril 4-8 mg/daily vs placebo using a multicentre, randomised, double-blind, parallel group design. Of the 191 patients entered, 183 completed 8 weeks of double-blind therapy. Average age was 72-73 years. Supine and standing BP at the end of the placebo run-in period were 173/96 vs 168/96 mm Hg. BPs were measured in the morning, 20-25 h after the previous day's dose (ie, at the end of the dosing interval). In the placebo group, supine and standing diastolic BP decreased by 3-4 mm Hg, and systolic BP by 6-7 mm Hg. In the perindopril-group, diastolic BP decreased by 6-7 mm Hg and systolic BP by 10-13 mm Hg (both P < 0.01 vs placebo). These data indicate a substantial placebo response of particularly systolic BP in older hypertensives and indicate the importance of a parallel placebo-group to assess the extent of the actual drug's effect. Perindopril caused additional decreases in diastolic BP by about 2 mm Hg, and in systolic BP by 4-5 mm Hg. The extent of this drug-effect may be less in older vs middle-aged hypertensives.
F H Leenen; J Tanner; C F McNally
Related Documents :
8105829 - Fenoldopam infusion for the treatment of postoperative hypertension.
12018559 - Status of lifestyle modifications in hypertension.
19000959 - Impact of patient-general practitioner short-messages-based interaction on the control ...
15668359 - Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials.
2442549 - The clinical pharmacology of lisinopril.
1747219 - White coat phenomenon in patients receiving antihypertensive therapy.
1935709 - Cardiotoxicity and hypertension in rats after oral lead exposure.
18829779 - Elevated blood pressure in relation to overweight and obesity among children in a rural...
17485009 - Value of ambulatory arterial stiffness index and 24-h pulse pressure to predict progres...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of human hypertension     Volume:  14     ISSN:  0950-9240     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-06-23     Completed Date:  2000-06-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  321-5     Citation Subset:  IM    
University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Blood Pressure / drug effects
Double-Blind Method
Hypertension / drug therapy*,  physiopathology
Perindopril / adverse effects,  therapeutic use*
Supine Position
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 82834-16-0/Perindopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effects of exercising muscle mass on post exercise hypotension.
Next Document:  Usefulness of the I/D angiotensin-converting enzyme genotype for detecting the risk of left ventricu...